About Zinc finger and BTB domain-containing protein 39
Zinc finger and BTB domain-containing protein 39 (ZBTB39) is a protein
from Homo sapiens identified by UniProt accession
O15060, 712 residues long.
MolForge cross-references it against 0 known binders and
19 disease associations.
Target properties
| Protein name | Zinc finger and BTB domain-containing protein 39 |
|---|
| UniProt accession | O15060 |
|---|
| Gene | ZBTB39 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 712 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O15060-F1 | alphafold | PREDICTED | 51.26 | — |
Amino-acid sequence (712 residues)
MGMRIKLQST NHPNNLLKEL NKCRLSETMC DVTIVVGSRS FPAHKAVLAC AAGYFQNLFL NTGLDAARTY VVDFITPANF EKVLSFVYTS ELFTDLINVG VIYEVAERLG MEDLLQACHS TFPDLESTAR AKPLTSTSES HSGTLSCPSA EPAHPLGELR GGGDYLGADR NYVLPSDAGG SYKEEEKNVA SDANHSLHLP QPPPPPPKTE DHDTPAPFTS IPSMMTQPLL GTVSTGIQTS TSSCQPYKVQ SNGDFSKNSF LTPDNAVDIT TGTNSCLSNS EHSKDPGFGQ MDELQLEDLG DDDLQFEDPA EDIGTTEEVI ELSDDSEDEL AFGENDNREN KAMPCQVCKK VLEPNIQLIR QHARDHVDLL TGNCKVCETH FQDRNSRVTH VLSHIGIFLF SCDMCETKFF TQWQLTLHRR DGIFENNIIV HPNDPLPGKL GLFSGAASPE LKCAACGKVL AKDFHVVRGH ILDHLNLKGQ ACSVCDQRHL NLCSLMWHTL SHLGISVFSC SVCANSFVDW HLLEKHMAVH QSLEDALFHC RLCSQSFKSE AAYRYHVSQH KCNSGLDARP GFGLQHPALQ KRKLPAEEFL GEELALQGQP GNSKYSCKVC GKRFAHTSEF NYHRRIHTGE KPYQCKVCHK FFRGRSTIKC HLKTHSGALM YRCTVCGHYS STLNLMSKHV GVHKGSLPPD FTIEQTFMYI IHSKEADKNP DS
Explore Zinc finger and BTB domain-containing protein 39 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets